Additional file 2: Figure S1. of Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Pediatric ACR30/50/70/90 improvement in patients receiving etanercept, adalimumab or tocilizumab as a first-line or second-line biologic agent. (PPT 172 kb)